Substitute for form 1449A/PTO  
(Modified)**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	A-72015/GKS/ THR (455675-080))
-------	---	----	---	------------------------	--------------------------------

**Complete if Known**

Application Number	09/724,965
Filing Date	November 28, 2000
First Named Inventor	LONBERG
Group Art Unit	1632
Examiner Name	A.M.S. Wehbe
Attorney Docket Number	A-72015/GKS/ THR (455675-080))

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	ER	5,545,806	08-13-1996	Lonberg, et al	
	ES	5,569,825	10-29-1996	Lonberg, et al	
	ET	5,591,669	01-07-1997	Krimpenfort et al	
	EU	5,612,205	03-18-1997	Kay et al.	
	EV	5,625,126	04-29-1997	Lonberg, et al	
	EW	5,661,016	08-26-1997	Lonberg, et al	
	EX	5,721,367	02-24-1998	Kay et al	
	EY	5,789,650	08-04-1998	Lonberg, et al	
	EZ	5,814,318	09-29-1998	Lonberg, et al	
	FA	5,939,598	08-17-1999	Kucherlapati et al	
	FB	6,023,010	02-08-2000	Krimpenfort et al	
	FC	6,075,181	06-13-2000	Kucherlapati et al	
	FD	6,150,584	11-21-2000	Kucherlapati et al	
	FE	6,162,963	12-19-2000	Kucherlapati et al	
	FF	6,114,598	09-05-2000	Kucherlapati et al	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	FG	WO 92/03917	03-19-1992	GenPharm Intl.		
	FH	WO 96/33735	10-31-1996	GenPharm Intl		
	FI	WO 97/13852	04-17-1997	GenPharm Intl		
	FJ	WO 98/24884	06-11-1998	GenPharm Intl		
	FK	WO 98/24893	06-11-1998	Abgenix		
	FL					

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	FM	Harding FA, Lonberg N., "Class switching in human immunoglobulin transgenic mice", <i>Ann N Y Acad Sci.</i> , 764: 536-46 (1995).	

Examiner Signature	<i>ALLIE</i>	Date Considered	12/3/04
--------------------	--------------	-----------------	---------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1128514\_2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  
(Modified)**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/724,965
Filing Date	November 28, 2000
First Named Inventor	LONBERG
Group Art Unit	1632
Examiner Name	A.M.S. Wehbe
Attorney Docket Number	A-72015/GKS/ THR (455675-080))

Sheet	2	of	2
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7 <sup>6</sup>
FW	FN	Jakobovits A, et al., "Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs", <i>Ann N Y Acad Sci.</i> 764:525-35 (1995)	
	FO	Jakobovits A., "Production of fully human antibodies by transgenic mice", <i>Curr Opin Biotechnol.</i> : 6(5):561-6 (1995).	
	FP	Jakobovits A, "YAC vectors. Humanizing the mouse genome", <i>Curr Biol.</i> , 4(8):761-3 (1994)	
	FQ	Lonberg N., et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications", <i>Nature</i> . 368(6474): 856-859 (1994)	
	FR	Lonberg N, Huszar D., "Human antibodies from transgenic mice", <i>Int Rev Immunol.</i> 13(1): 65-93 (1995).	
	FS	Storb, U. et al., "Expression of microinjected immunoglobulin kappa gene in transgenic mice", <i>Banbury Reports</i> , 20:197-207 (1985)	
	FT	Takeda, S. et al, "Deletion of the immunoglobulin kappa chain intron enhancer abolishes kappa chain gene rearrangement <i>in cis</i> but not lambda chain gene rearrangement <i>in trans</i> ", <i>EMBO J.</i> , 12(6): 2329-2336 (1993)	
	FU	Taylor, L.D. et al, "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins", <i>Nucl. Acids Res.</i> , 20:6287-6295, (1992)	
	FV	Taylor, L.D. et al, "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM", <i>Intl. Immunol.</i> , 6(4):579-591 (1994)	
	FW	Tuallon, N. et al., "Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in mu and gamma transcripts " <i>PNAS</i> , 90:3720-3724	
	FX	Zou, Y-R., et al., "Gene targeting in the Ig kappa locus: Efficient generation of lambda chain-expressing B cells, independent of gene rearrangements in Ig kappa", <i>EMBO J.</i> , 12(3):811-820 (1993)	

Examiner Signature		Date Considered	12/3/04
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1128514\_2